Newly Refined Mammotome Revolve™ System
Features a simple and intuitive user interface that minimizes steps to complete procedures.
RSNA® 2024 Annual Meeting
Join us to see our latest product innovations
December 1-5 • Booth #2100 • Chicago, IL
Watch the HydroMARK™ Plus Marker Webinar
See clinical cases with the HydroMARK™ Plus Breast Biopsy Site Marker from both the biopsy and OR suites!
HydroMARK™ Plus Markers
Same great benefits of the original HydroMARK™ markers, with added features designed to alleviate displacement, enhance visibility, and ease of locating.1,2,3
Now offering two shapes: Dragonfly and Hummingbird
Distinct from every angle
The LumiMARK™ marker features three distinctive, multifaceted 3D shapes designed for easy identification from any angle.5
Products & Solutions
At Mammotome, we are committed to providing best-in-class technology to help clinicians accurately diagnose breast cancer. Never forgetting that at the heart of each breast cancer diagnosis is the patient. Our product portfolio covers two integrated main steps in the overall breast cancer treatment pathway: breast biopsy and local surgical treatments.
Neoprobe® Gamma Detection System
Neoprobe® GDS offers exceptional accuracy, effortless operation and advanced clinical capability.
Mammotome® Elite System
The Mammotome® Elite breast biopsy device combines vacuum-assisted biopsy tissue quality with the ease and speed of a spring-loaded core needle.
Mammotome® Markers
Mammotome® Markers offer clinicians the most comprehensive portfolio available, providing a customized solution for every breast biopsy need.
Sentimag® Localization Platform
Four techniques in one platform allow for more surgical options than any other non-gamma localization system.
Mammotome DualCore™ System
The Mammotome DualCore™ system is lightweight, precise, and reliable, offering a spring-loaded action for quality sampling capability.
Mammotome Service and Support
Service and support from the team that knows your Mammotome products best.
Mammotome Revolve™ System
Redefining procedural efficiency without compromising tissue quality – from positioning to diagnosis.
Mammotome Confirm™ SRS
Veryify the presence of microcalcifications during stereotactic biopsies quickly and easily.
XPERT® 40 SRS
When you need to identify fine details, in a wide range of specimens, in a short amount of time.
1. HydroMARK™ Device Test – PCR-000414, Summative Usability
2. HydroMARK™ Design Plan – ADD-00013 Rev G, Page 15
3. HydroMARK™ Device Test – PCR-000299, SDR0098 Vacuum Suction Testing
4. As compared to 14G spring-fired core needle devices
5. LumiMARK™ Device Tests: PCR-000340 System Design, PCR-000579 Summative Usability, ES-002647 Claims Assessment
Upcoming Events & Initiatives
Solving for Marker Displacement and Enabling Localization Best Practices with the HydroMARK™ Plus Marker
See clinical cases with the HydroMARK™ Plus Breast Biopsy Site Marker from both the biopsy and OR suites during this on-demand webinar!
Mammotome Expands the HydroMARK™ Plus Breast Biopsy Site Marker Portfolio
Mammotome is excited to announce an addition to the recently launched HydroMARK™ Plus Breast Biopsy Site Marker line.
About Us
At Mammotome, we are a global team dedicated to advancing breast care. Our passion is driving innovative technologies that create efficiencies for clinicians, while never forgetting that at the heart of every breast cancer journey is a patient.
Learn how we transformed the future of breast cancer diagnostics and continue to discover new opportunities to deliver better solutions and care.
850+
Dedicated
Associates
9
Global
Locations
65
Countries
Where Our Products Are Sold
Join the Team
Mammotome associates know that every moment matters when it comes to advancing breast cancer diagnostics and surgical solutions. We’re a global team of engineers, designers, communicators, strategists and specialists focused on improving patient outcomes. Inspired to grow every day, our collaborative, diverse, high-performing team is a trusted leader in the breast care industry. And as part of Danaher, we’re growing fast and innovating faster.
